Formulated siRNAs targeting <i>Rankl</i> prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models

Abstract excerpt

The development of osteosarcoma, the most common malignant primary bone tumor is characterized by a vicious cycle established between tumor proliferation and paratumor osteolysis. This osteolysis is mainly regulated by the receptor activator of nuclear factor κB ligand (RANKL). Preclinical studies have demonstrated that Rankl blockade by soluble receptors is an effective strategy to prevent osteolytic lesions...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bone health and treatments
• Share to Bone Metabolism and Diseases
• Share to MicroRNA in disease regulation